The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released appropriate use criteria (AUC) guidelines for the use of somatostatin receptor PET to diagnose neuroendocrine tumors.
The AUC document is available in the January 2018 issue of the Journal of Nuclear Medicine and features 12 different clinical scenarios for the technology.
The SNMMI previously published AUC guidelines for FDG-PET/CT in restaging and treatment response for malignant disease; bone scintigraphy in prostate and breast cancer; ventilation/perfusion imaging for pulmonary embolism; and hepatobiliary scintigraphy for abdominal pain.
The society's guidance oversight committee currently is working on AUC parameters for gastrointestinal transit, infection imaging, PET myocardial perfusion imaging, prostate cancer imaging, and thyroid imaging and therapy.
